Latest Breaking News On - Kazia therapeutics ltd - Page 23 : comparemela.com

Share this article Share this article SYDNEY, March 1, 2021 /PRNewswire/ Kazia Therapeutics Limited (ASX: KZA;NASDAQ: KZIA), an Australian oncology-focused biotechnology company, is pleased to announce that it has entered into an exclusive worldwide license agreement with Oasmia Pharmaceutical AB (STO: OASM), an innovation-focused specialty pharmaceutical company, for Cantrixil (TRX-E-002-1), a clinical-stage, first-in-class drug candidate under development for the treatment of ovarian cancer. Key Points Oasmia will assume worldwide exclusive rights to develop and commercialise Cantrixil for all indications, with an initial focus on ovarian cancer Under the terms of the agreement, Oasmia will make an upfront payment of

New south walesPrnewswire kazia therapeutics limitedKazia therapeutics ltdTherapeutics limitedOasmia pharmaceuticalபுதியது தெற்கு வேல்ஸ்சிகிச்சை வரையறுக்கப்பட்டவை